Add like
Add dislike
Add to saved papers

Bicyclic RGD-peptides with Exquisite Selectivity for the Integrin αvβ3 Receptor using a 'Random Design' Approach.

We describe the identification of bicyclic RGD-peptides with high affinity and selectivity for integrin αvβ3 via high-throughput screening of partly randomized libraries. Peptide libraries (~700 different compounds) comprising the universal integrin-binding sequence Arg-Gly-Asp (RGD) in the first loop and a randomized sequence XXX (X being one of 18 canoni-cal L-amino acids) in the second loop, both enclosed by either an L- or D-Cys residue, were converted to bicyclic peptides via reaction with 1,3,5-tris(bromomethyl)benzene (T3). Screening of 1st generation libraries yielded lead bicyclic inhibitors dis-playing submicromolar affinities for integrin αvβ3 (e.g. CT3HEQcT3RGDcT3, IC50: 195 nM). Next generation (2nd and 3rd) librar-ies were obtained by partially varying the structure of the strongest lead inhibitors and screening for improved affinities and selectivities. In this way, we identified the highly selective bicyclic αvβ3-binders CT3HPQcT3RGDcT3 (IC50=30 nM), CT3HPQCT3RGDcT3 (IC50=31 nM), and CT3HSQCT3RGDcT3 (IC50=42 nM) with affinities comparable to that of a knottin-RGD-type peptide (32 amino acids, IC50=38 nM) and outstanding selectivities over integrins αvβ5 (IC50 >10,000 nM) and α5β1 (IC50 >10,000 nM). Affinity measurements using Surface Plasmon-enhanced Fluorescence Spectroscopy (SPFS) yielded Kd values of 0.4 and 0.6 nM for Cy5-labeled bicycle CT3HPQcT3RGDcT3 and RGD 'knottin' peptide, respectively. In vitro stain-ing of HT29 cells with Cy5-labeled bicycles using confocal microscopy revealed strong binding to integrins in their natural environment, which highlights the high potential of these peptides as markers of integrin-expression.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app